Determine the necessary mass, volume, or concentration for preparing a solution.
for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at -20°C Ships Ice chest + Ice pads Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
H-Ile-Lys-Val-Ala-Val-OH is one of the most potent active sites of laminin-1. H-Ile-Lys-Val-Ala-Val-OH promotes cell adhesion, neurite outgrowth, and tumor growth. H-Ile-Lys-Val-Ala-Val-OH stimulates BMMSC population growth and proliferation by activating MAPK/ERK1/2 and PI3K/Akt signalling pathways
In Vitro
H-Ile-Lys-Val-Ala-Val-OH (0-2.5 mM, 0-48 h) induces proliferation and proliferating cell nuclear antigen (PCNA) synthesis of bone marrow mesenchymal stem cell (BMMSC). H-Ile-Lys-Val-Ala-Val-OH (5 mM, 24 h) induces the BMMSC cell cycle for cells to enter S phase from G0/G1 and arrests them from entering G2/M phase. H-Ile-Lys-Val-Ala-Val-OH (0-2.5 mM, 0-48 h) activats MAPK/ERK and PI3K/Akt signalling pathways by enhancing phosphorylation levels of ERK1/2 and Akt in the BMMSCs. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation AssayCell Line: BMMSC Concentration: 0, 0.004, 0.02, 0.1, 0.5 and 2.5 mM Incubation Time: 0, 12, 24, 36, 48 h Result: Stimulated proliferating cell nuclear antigen (PCNA) synthesis and induced proliferation of bone marrow mesenchymal stem cell (BMMSC) in a dose- and time-dependent manner. Cell Cycle AnalysisCell Line: BMMSC Concentration: 5 mM Incubation Time: 24 h Result: Induced the BMMSC cell cycle for cells to enter S phase from G0/G1 and arrested them from entering G2/M phase; the increased proportion of S phase in cell cycle was considered to be a sign of BMMSC proliferation. Western Blot AnalysisCell Line: BMMSC Concentration: 0, 0.004, 0.02, 0.1, 0.5 and 2.5 mM Incubation Time: 0, 12, 24, 36, 48 h Result: Increased significantly the levels of p-ERK1/2 and p-Akt in a dose- and time-dependent manner.
Form:Solid
IC50& Target:ERK1 ERK2 Akt
| Isomeric SMILES | CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)O)N |
|---|---|
| PubChem CID | 131343 |
| Molecular Weight | 528.69 |
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →| Solubility | H2O Peptide Solubility and Storage Guidelines: 1. Calculate the length of the peptide. 2. Calculate the overall charge of the entire peptide according to the following table: Contents Assign value Acidic amino acid Asp (D), Glu (E), a |
|---|---|
| Molecular Weight | 528.700 g/mol |
| XLogP3 | -2.700 |
| Hydrogen Bond Donor Count | 7 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 17 |
| Exact Mass | 528.364 Da |
| Monoisotopic Mass | 528.364 Da |
| Topological Polar Surface Area | 206.000 Ų |
| Heavy Atom Count | 37 |
| Formal Charge | 0 |
| Complexity | 775.000 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 6 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| The total count of all stereochemical bonds | 0 |
| Covalently-Bonded Unit Count | 1 |